Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES T HEYWOOD

Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology

NPI
1285612457
CMS profile
13194
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$118,480.96

179 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–179 of 179 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES T HEYWOOD

NPI 1285612457 · CMS profile ID 13194

Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–179 of 179 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285612457?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES T HEYWOOD, NPI 1285612457, CMS profile ID 13194. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–179 of 179 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285612457?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMES T HEYWOOD, NPI 1285612457, CMS profile ID 13194. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–179 of 179 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285612457?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMES T HEYWOOD, NPI 1285612457, CMS profile ID 13194, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–179 of 179 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1285612457?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

179 matching records · $118,480.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 179 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–179 of 179.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CVRx, Inc. $80.3303/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219175270 CMS
Actelion Pharmaceuticals US, Inc. $4.1302/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174180109 CMS
CVRx, Inc. $51.0902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219175266 CMS
CVRx, Inc. $77.5002/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219175268 CMS
United Therapeutics Corporation $303.9702/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526958 CMS
United Therapeutics Corporation $24.4902/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547702 CMS
Actelion Pharmaceuticals US, Inc. $3,270.0002/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174180815 CMS
Boston Scientific Corporation $385.0002/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181197696 CMS
Boston Scientific Corporation $2,900.0002/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181197698 CMS
Actelion Pharmaceuticals US, Inc. $5.5002/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174181006 CMS
CVRx, Inc. $13.4402/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218115175 CMS
Merck Sharp & Dohme LLC $29.7002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238173554 CMS
PFIZER INC. $22.4102/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231543948 CMS
Actelion Pharmaceuticals US, Inc. $15.5902/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174179751 CMS
United Therapeutics Corporation $491.0002/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526944 CMS
CVRx, Inc. $160.2302/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218113165 CMS
Boston Scientific Corporation $3,500.0002/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181197692 CMS
Boston Scientific Corporation $385.0002/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181197694 CMS
Impulse Dynamics (USA) Inc. $85.2802/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223106886 CMS
Actelion Pharmaceuticals US, Inc. $14.7301/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174180228 CMS
SCPHARMACEUTICALS INC. $18.1101/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228174478 CMS
Actelion Pharmaceuticals US, Inc. $22.5301/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174180141 CMS
Merck Sharp & Dohme LLC $21.7701/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238216972 CMS
CVRx, Inc. $52.2301/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218110647 CMS
Merck Sharp & Dohme LLC $26.6301/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238215076 CMS
Actelion Pharmaceuticals US, Inc. $12.7401/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174179799 CMS
CVRx, Inc. $340.9601/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1218109790 CMS
Amgen Inc. $14.3401/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227105280 CMS
CVRx, Inc. $4.9501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218107196 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $286,962.47 366
PY2020 $157,880.52 224
PY2021 $131,192.00 252
PY2022 $185,245.87 306
PY2023 $144,822.83 209
PY2024 $161,890.79 226
PY2025 $118,480.96 179

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $228,017.93 18
PY2024 Principal investigator $305,137.50 19
PY2023 Principal investigator $71,096.00 22
PY2022 Principal investigator $90,885.30 19
PY2021 Principal investigator $23,251.30 13
PY2020 Principal investigator $91,819.80 10
PY2019 Recipient $2,123.83 4
PY2019 Principal investigator $149,080.63 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $180,119.46 12/31/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232936738
Principal investigator 1 Janssen Research & Development, LLC $4,728.00 12/01/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441009
Principal investigator 1 Janssen Research & Development, LLC $300.00 10/30/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440982
Principal investigator 1 Merck Sharp & Dohme LLC $5,785.47 10/21/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232936904
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/02/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440941
Principal investigator 1 Janssen Research & Development, LLC $5,492.00 09/04/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440929
Principal investigator 1 Janssen Research & Development, LLC $4,440.00 09/01/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440952
Principal investigator 1 Janssen Research & Development, LLC $7,200.00 08/21/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440977
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 07/28/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441004
Principal investigator 1 Janssen Research & Development, LLC $1,914.00 06/26/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440957
Principal investigator 1 Janssen Research & Development, LLC $1,214.00 05/26/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440993
Principal investigator 1 Janssen Research & Development, LLC $1,214.00 04/28/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440970
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/07/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440946
Principal investigator 1 Janssen Research & Development, LLC $2,628.00 03/24/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175441014
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 03/03/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440998
Principal investigator 1 Janssen Research & Development, LLC $2,805.00 02/13/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440934
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 02/13/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440963
Principal investigator 1 Janssen Research & Development, LLC $3,128.00 01/27/2025 Covered Recipient Teaching Hospital
Scripps Mercy Hospital
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175440988